Bumetanide: potent new "loop" diuretic. 1972

M J Asbury, and P B Gatenby, and S O'Sullivan, and E Bourke

Bumetanide, a pharmacologically new diuretic, was evaluated in 27 subjects. Its onset of action was within 30 minutes with a peak at 90 minutes and a total duration of action of about 270 minutes. In a controlled study in oedematous patients it was equipotent with frusemide at one-fortieth the molar dosage and did not differ from frusemide with regard to its pattern of electrolyte excretion. On continuous oral administration for eight days it produced effective diuresis with minimal alteration in biochemical and haematological status. The only adverse effect was gastric discomfort in one patient.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010636 Phenols Benzene derivatives that include one or more hydroxyl groups attached to the ring structure.
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D002082 Butylamines Isomeric amines of butane, where an amino group replaces a hydrogen on one of the four carbons. They include isobutylamine, n-Butylamine, sec-Butylamine, and tert-Butylamine.
D002712 Chlorides Inorganic compounds derived from hydrochloric acid that contain the Cl- ion. Chloride,Chloride Ion Level,Ion Level, Chloride,Level, Chloride Ion
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004232 Diuretics Agents that promote the excretion of urine through their effects on kidney function. Diuretic,Diuretic Effect,Diuretic Effects,Effect, Diuretic,Effects, Diuretic
D004487 Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE. Dropsy,Hydrops,Anasarca

Related Publications

M J Asbury, and P B Gatenby, and S O'Sullivan, and E Bourke
October 1976, Clinical pharmacology and therapeutics,
M J Asbury, and P B Gatenby, and S O'Sullivan, and E Bourke
June 1983, The Medical letter on drugs and therapeutics,
M J Asbury, and P B Gatenby, and S O'Sullivan, and E Bourke
March 1987, Iowa medicine : journal of the Iowa Medical Society,
M J Asbury, and P B Gatenby, and S O'Sullivan, and E Bourke
November 1983, Drug intelligence & clinical pharmacy,
M J Asbury, and P B Gatenby, and S O'Sullivan, and E Bourke
September 1975, Lakartidningen,
M J Asbury, and P B Gatenby, and S O'Sullivan, and E Bourke
January 1974, International urology and nephrology,
M J Asbury, and P B Gatenby, and S O'Sullivan, and E Bourke
January 1981, Journal of clinical pharmacology,
M J Asbury, and P B Gatenby, and S O'Sullivan, and E Bourke
August 1974, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
M J Asbury, and P B Gatenby, and S O'Sullivan, and E Bourke
January 1978, Acta oto-laryngologica,
M J Asbury, and P B Gatenby, and S O'Sullivan, and E Bourke
August 1975, Neuropharmacology,
Copied contents to your clipboard!